The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314.
Nordson Corporation
NDSN · a US exchange · USD · Market cap $17.5B · 8,200 employees
Nordson Corporation engineers, manufactures, and markets products and systems to dispense, apply, and control adhesives, coatings, polymers, sealants, biomaterials, medical components, and other fluids.
FAIL · Does not pass the screenAt the last full screen
2026-09-09
Screened 2026-09-09 · the tape above runs as of 23:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 313.94 against the desk's fair-value range, base estimate 309.43, over the last year.
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Nordson Corporation holds its Markup at $313.94. Consolidating, no directional conviction, held for 248 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 248 days |
| Price at the screen | $313.94 |
| Valuation | 31.78 trailing · 24.26 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.97 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 35.36% | Below 33% | Interest-bearing debt is 35.4% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 11.18% | Below 49% | Money owed to the company is 11.2% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.11% | Below 5% | Only 0.1% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Our framework reads AVOID: it trades above our $309.43 fair value estimate, moderate competitive moat, 10.30% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. The price runs 1.4% above the base estimate.
Third-party analyst targets: 7 covering, consensus None. The average target sits +15% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsNordson sits at fair value yet fails ethics
Picture a factory line where every seal, coating and medical component needs precise fluid control. Nordson supplies that equipment across dozens of end markets and grows revenue at 8 percent a year with an 18 percent profit margin and 17 percent ROE. The shares trade right on our fair value estimate, leaving no margin of safety.
We pass for one clear reason. The company fails our ethical screen on its debt ratio, a structural issue that outweighs the moderate moat and steady growth. Analyst targets sit higher, yet price and ethics together make the case for avoidance.
High leverage leaves the business exposed if rates stay elevated or demand softens. A moderate moat offers some protection, but not enough to offset the ethical red flag at current valuation. Analysis, not advice.
| Forward P/E | 24.3xexpensive even after accounting for its growth |
| Trailing P/E | 31.8xa premium valuation |
| EPS, trailing | 9.88 |
| EPS, forward | 12.94 |
| Revenue growth | +10.3%steady growth |
| Profit margin | 18.6%healthy profit margins |
| Return on equity | 17.8%a solid return on shareholder capital |
| FCF yield | 3.51% |
| Dividend yield | 116.00% |
| Debt to equity | 0.56moderate, manageable leverage |
| Current ratio | 1.82healthy short-term liquidity |
| Beta | 0.97steadier than the market |
| Short interest, float | 0.03% |
| 52-week range | 220.47 - 339.12 |
| Moat | MODERATE |
| Market cap | $17.5B |
| Employees | 8,200 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeNDSN trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (7 analysts) rates it buy, with a mean price target of $314.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-01 | CLAYTON ANNETTE K | Director | 270 | $76,464 | |
| 2026-04-30 | MAPES CHRISTOPHER L | Director | 43 | $12,403 | |
| 2026-04-30 | DEFORD JOHN A | Director | 87 | $25,095 | |
| 2026-04-17 | SUBRAMANIAN SRINIVAS | Officer | 3,100 | $868,000 | |
| 2026-04-17 | SUBRAMANIAN SRINIVAS | Officer | 1,900 | $204,535 | |
| 2026-04-15 | MORRIS MILTON MAYO | Director | 245 | $67,098 | |
| 2026-04-08 | HALL JUSTIN E | Officer | 716 | $197,487 | |
| 2026-02-24 | NAGARAJAN SUNDARAM | Chief Executive Officer | 41,800 | $12,258,268 | |
| 2026-02-24 | KELLEY JOSEPH P | Officer | 8,725 | $2,556,788 | |
| 2026-02-24 | KELLEY JOSEPH P | Officer | 8,434 | $1,625,296 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-05-01 | Ro Khanna | Democrat | sell | 15K–50K |
| 2024-05-03 | Tommy Tuberville | Republican | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $281.85 | -0.9% | · | $991 | -0.9% |
| 2 months | $275.28 | +1.4% | · | $1,014 | +1.4% |
| 3 months | $266.88 | +4.6% | $0.82 | $1,049 | +4.9% |
| 6 months | $232.90 | +19.9% | $1.64 | $1,206 | +20.6% |
| 1 year | $220.42 | +26.7% | $3.24 | $1,281 | +28.1% |
| 2 years | $219.85 | +27.0% | $5.58 | $1,295 | +29.5% |
| 3 years | $224.15 | +24.6% | $8.30 | $1,283 | +28.3% |
| 5 years | $210.46 | +32.7% | $12.94 | $1,388 | +38.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever NDSN does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.